Johnson & Johnson hasn't allowed competition for its top - selling drug Remicade and
blockbuster diabetes drug Invokana plus sluggishness in consumer healthcare sales to get in the way of growth.
Merck's
blockbuster diabetes drug JANUVIA / JANUMET (and now # 2 seller behind KEYTRUDA) also performed well (+7 %), as did several younger assets including BRIDEON (+38 %) and SIMPONI (+26 %).
Not exact matches
Without it, Lilly is counting on other fresh market entries to pick up the slack, including
diabetes drug Jardiance and Basaglar, its new biosimilar version of Sanofi's insulin
blockbuster Lantus.